Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | PLAAT3 | P53816 | 2/20 | 0.38 |
| ▸ | PLAAT5 | Q96KN8 | 2/20 | 0.38 |
| ▸ | PLAAT2 | Q9NWW9 | 2/20 | 0.38 |
| ▸ | PLAAT4 | Q9UL19 | 2/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3597026 | 0.86 | ALDH1A1 (0.45) | ALDH1A1KMT2ASMN1; SMN2HPGDMEN1 | |
| SCHEMBL3598008 | 0.82 | ADRB2 (0.47) | ALDH1A1KMT2ASMN1; SMN2ADRB2 | |
| SCHEMBL2213107 | 0.81 | ADRB2 (0.60) | ADRB2 | |
| SCHEMBL3583814 | 0.80 | ALDH1A1 (0.45) | ALDH1A1KMT2ASMN1; SMN2HPGDMEN1 | |
| Trifluoroacetic Acid SCHEMBL2206570 | 0.78 | ADRB2 (0.56) | ADRB2 | |
| SCHEMBL2213487 | 0.76 | ADRB2 (0.58) | ADRB2 | |
| SCHEMBL3592390 | 0.73 | ADRB2 (0.42) | TRPV1ADRB2 | |
| SCHEMBL3598956 | 0.73 | ADRB2 (0.36) | ALDH1A1KMT2AMEN1MAPTRXFP1 | |
| SCHEMBL3597947 | 0.73 | ADRB2 (0.43) | KMT2AMEN1TAAR1ADRB2 | |
| SCHEMBL2213530 | 0.72 | ADRB2 (0.53) | ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142646-A1 | Novel Compounds 621 | ASTRAZENECA AB (SE) | 2012-06-07 | — | — | US | disclosed |
| US-20100056508-A1 | AMINE DERIVATIVES AND THEIR USE IN BETA-2-ADRENORECEPTOR MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142646-A1 | Novel Compounds 621 | AR, ADRA1D, ADRA1B | ALDH1A1 656/4885KMT2A 1490/4885SMN1; SMN2 2741/4885 |
| US-20100056508-A1 | AMINE DERIVATIVES AND THEIR USE IN BETA-2-ADRENORECEPTOR MEDIATED DISEASES | ADRB2, ADRB1, ADRA2A | ALDH1A1 560/4885KMT2A 976/4885SMN1; SMN2 955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.